Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL01Antineoplastic agents
- Pharmacological subgroupL01F
- Chemical subgroupL01FF
- Chemical substanceL01FF06Cemiplimab
Where it is registered
Each register and historical list with its number of registrations and a few of them.
At a glance
- ATC code
- L01FF06
- Registers
- 7
- Historical lists
- 1
- Registrations
- 11
- With their own page
- 8
- Companies
- 7
All medicines with Cemiplimab
Human medicines from every register that match Cemiplimab by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
11 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Libtayo | United States | 350MG | injectable | Marketed | Regeneron Pharmaceuticals |
| Libtayo 350 MG Concentrado Para Solucion Para Perfusion | Spain | 350 mg | concentrado para solución para perfusión | Marketed | Regeneron Ireland Designated Activity Company |
| Libtayo | European Union | Authorised | Regeneron Ireland Designated Activity Company (DAC) | ||
| Libtayo 350 MG Concentrado Para Solucion Para Perfusion | Spain | 350 mg | concentrado para solución para perfusión | Authorised | Regeneron Ireland Designated Activity Company |
| Libtayo 350 mg concentraat voor oplossing voor infusie | Netherlands | Concentraat voor oplossing voor infusie | Authorised | Regeneron Ireland Designated Activity Company | |
| Libtayo | Canada | 350 MG / 7 ML | Solution | Marketed | Regeneron Canada Company |
| Libtayo | Brazil | Authorised | Adium S.A. | ||
| Libtayo | Croatia | Marketed | |||
| Libtayo | Canada | 250 MG / 5 ML | Solution | Cancelled | Sanofi-Aventis Canada INC |
| Libtayo | Brazil | Cancelled | Sanofi Medley Farmacêutica Ltda. | ||
| LIBTAYO 350 mg | Romania | 50 mg/ ml | conc. pt. sol. perf. | Status unknown | Regeneron Ireland Dac |